MIR2467: A Potential Drug Target and Biomarker for Cancer (G100616360)
MIR2467: A Potential Drug Target and Biomarker for Cancer
Molecular Intelligence (MIT) has identified a potential drug target and biomarker for cancer, MIR2467. This protein is a key regulator of cell division and has been implicated in various types of cancer. MIR2467 has also been identified as a potential biomarker for cancer, making it an attractive target for drug development.
The MIR2467 protein is a member of the microRNA (miRNA) family, a class of non-coding RNAs that play a critical role in post-transcriptional gene regulation. MIR2467 is expressed in a variety of tissues and has been shown to regulate cell division, cell growth, and apoptosis.
In cancer, MIR2467 has been implicated in the development and progression of various types of cancer. For example, MIR2467 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, MIR2467 has been shown to be associated with cancer-related apoptosis, as it has been shown to promote cell death in cancer cells.
Despite these insights, much work remains to be done in order to fully understand the role of MIR2467 in cancer. One of the main challenges in studying MIR2467 is its complex regulation. MIR2467 is regulated by a variety of factors, including miRNA targets, co-factors, and enzymes.
In order to study MIR2467 more fully, researchers have used a variety of techniques, including RNA interference, RNA sequencing, and mass spectrometry. These techniques have allowed researchers to identify MIR2467's miRNA targets and to study the role of MIR2467 in cell division and apoptosis.
One of the most promising avenues for studying MIR2467 is its potential as a drug target. By inhibiting MIR2467, researchers can study its effects on cell division and apoptosis, and identify potential therapeutic targets for cancer. Additionally, MIR2467 has been shown to be a potential biomarker for cancer, making it an attractive target for drug development.
In order to develop MIR2467 as a drug target, researchers will need to conduct preclinical studies to determine its safety and efficacy. This will involve administering MIR2467 to cancer cells and studying its effects on cell growth, division, and apoptosis. Researchers will also need to identify potential drug candidates and test them in preclinical models of cancer.
If MIR2467 is found to be a promising drug target, researchers will then proceed with clinical trials to study its effects in cancer patients. This will involve administering MIR2467 to cancer patients and studying its effects on cell growth, division, and apoptosis. Researchers will also need to monitor the safety and efficacy of MIR2467 in cancer patients and make any necessary adjustments to its use.
In conclusion, MIR2467 is a promising drug target and biomarker for cancer. Its regulation of cell division and apoptosis makes it an attractive target for drug development, and its potential as a biomarker for cancer makes it an important step in the development of new cancer therapies.
Protein Name: MicroRNA 2467
The "MIR2467 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR2467 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127 | MIR3128 | MIR3129 | MIR3130-1 | MIR3130-2 | MIR3131 | MIR3132 | MIR3133 | MIR3134 | MIR3135A | MIR3135B | MIR3136 | MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143 | MIR3144 | MIR3145 | MIR3146 | MIR3147 | MIR3147HG | MIR3148 | MIR3149 | MIR3150A | MIR3150B | MIR3151 | MIR3152 | MIR3153 | MIR3154 | MIR3155A | MIR3155B | MIR3156-1 | MIR3156-2 | MIR3156-3 | MIR3157 | MIR3158-1
